April 17, 2023
Memphis news station WMC-TV highlighted Caracole and the University of Cincinnati's partnership and implementation of a harm reduction vending machine.
April 14, 2023
Physics World highlighted research led by the University of Cincinnati's Nalinikanth Kotagiri that shows a proof of concept for using engineered bacteria as an adapter to deliver targeted radionuclide treatment to tumors.
April 14, 2023
The University of Cincinnati Cancer Center's Melinda Butsch Kovacic and colleagues will present research abstracts on several community outreach and engagement initiatives at the American Association for Cancer Research Annual Meeting 2023, held in Orlando, Florida, April 14-19.
April 14, 2023
University of Cincinnati Cancer Center researchers will present more than a dozen abstracts at the American Association for Cancer Research Annual Meeting 2023, held in Orlando, Florida, April 14-19, including findings that could advance treatments for head and neck and breast cancers.
April 13, 2023
The University of Cincinnati's Amanda Jackson joined 55KRC's Simply Medicine program to discuss the UP-NEXT ovarian cancer clinical trial.
April 13, 2023
The University of Cincinnati is enrolling patients in an Imvax study that will test the effectiveness of a personalized vaccine approach to fight deadly brain tumors.
April 12, 2023
The University of Cincinnati's Christine Wilder, MD, spoke with the Cincinnati Enquirer about Hamilton County data that overdose deaths in 2022 dropped for the first time in six years.
April 11, 2023
The University of Cincinnati's Atsuo Sasaki, PhD, is leading a multidisciplinary team that received National Institutes of Health funding to learn more about how an enzyme that was previously overlooked helps regulate lysosome and cellular function.
April 10, 2023
The University of Cincinnati's Kelly Dobos walked the Wall Street Journal through ingredients in a commercially available foundation from a "clean beauty" brand.
April 7, 2023
Drug Discovery News highlighted research coauthored by the University of Cincinnati's Timothy Phoenix that found a gene called FOXR2 is abnormally expressed in more than 70% of cancer types sampled and could be a potential target for new treatments.